Skip to content

Acute Hypertensive Cerebral Hemmorrhage Surgery

The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery: a Multi-center Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04957849
Acronym
NET-OCEAN
Enrollment
1000
Registered
2021-07-12
Start date
2022-01-01
Completion date
2025-06-30
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Intracerebral Hemorrhage

Keywords

neuroendoscope, trans-occipital approach, Acute Hypertensive Cerebral Hemmorrhage, Low-drainage Surgery

Brief summary

The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery: a Multi-center Clinical Trial

Detailed description

To evaluate the effect of different surgical approaches on the prognosis of patients with hypertensive intracerebral hemorrhage, hypertensive patients who met the diagnostic criteria of American guidelines for the treatment of adult spontaneous intracerebral hemorrhage (2015) were selected. The time from onset to admission was less than 8 hours. Blood routine examination, liver and kidney function, coagulation system, infectious diseases and other examinations were performed before operation, with emergency surgical indications, They were divided into two groups: transfrontal keyhole approach and transoccipital keyhole approach. Emergency endoscopic hematoma removal was performed. The patients were systematically evaluated and followed up at 1 week, 1 month, 3 months, 6 months and 12 months after operation to observe the improvement of consciousness, GCS score, postoperative rebleeding (appearance, bleeding volume, location, broken into ventricle, etc.), The prognosis was evaluated by ADL score, GCS score, gos score, modified Rankin scale, Mrs scale and ICH Score (GCS, hematoma volume, intraventricular hemorrhage, infratentorial source, patient age, etc.).

Interventions

PROCEDUREThe Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery

The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery

PROCEDUREEndoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach

Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach

Sponsors

Beijing Tiantan Hospital
CollaboratorOTHER
Huashan Hospital
CollaboratorOTHER
Tianjin Medical University General Hospital
CollaboratorOTHER
First Affiliated Hospital of Fujian Medical University
CollaboratorOTHER
Peking Union Medical College Hospital
CollaboratorOTHER
Second Affiliated Hospital of Soochow University
CollaboratorOTHER
The First Affiliated Hospital of Nanchang University
CollaboratorOTHER
The General Hospital of Eastern Theater Command
CollaboratorOTHER
First Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
Shengjing Hospital
CollaboratorOTHER
ShuGuang Hospital
CollaboratorOTHER
Qianfoshan Hospital
CollaboratorOTHER
Shanghai Changzheng Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosed patients with spontaneous cerebral hemorrhage in the basal ganglia (in line with the diagnostic criteria of the American Adult Spontaneous Cerebral Hemorrhage Treatment Guidelines (2015)). 2. Head CT showed; hematoma volume ≥ 30ml, intraventricular hemorrhage is not counted as hemorrhage volume. 3. Time from onset to hospital admission ≤8h. 4. The age of the patient is 15-75 years old. 5. Glasgow Coma Score (GCS)\> 5 points. 6. The patient/family knows and signs the informed consent form. 7. Have a clear history of hypertension in the past.

Exclusion criteria

1. Bleeding caused by aneurysm, vascular malformation or tumor stroke. 2. Combined with a history of head injury or trauma. 3. There is more blood in the skull. 4. Past mental disorders or neurological dysfunction. 5. A history of procoagulant dysfunction or anticoagulant drugs. 6. Patients with complications such as liver and kidney dysfunction. 7. Those with poor compliance. 8. Pregnant patients. 9. With massive hemorrhage of the ventricle (the area of the hematoma in the CT side is larger than 1/2 of the transverse section), hemorrhage in the third and fourth ventricles with enlarged ventricles. 10. With late-stage cerebral herniation (bilateral dilated pupils, central respiratory and circulatory failure). 11. Severe cardiovascular and cerebrovascular diseases: such as myocardial infarction, cerebral infarction, coronary heart disease, myocarditis, malignant arrhythmia, etc. 12. Participate in other clinical research 3 months before enrollment. 13. The doctor in charge believes that the study plan cannot be followed. 14. Those who are or plan to become pregnant or breastfeeding. 15. Those who are known to be allergic to test drugs or related products.

Design outcomes

Primary

MeasureTime frameDescription
Clinical remission rate1 month postoperationThe evaluation criteria of complete remission: more than 85% of intracranial hematoma was cleared, mild brain edema, and the postoperative hospital stay was less than 2 weeks. The evaluation criteria of partial remission: the clearance rate of intracranial hematoma was 60% - 85%, the postoperative brain edema was obvious, and the postoperative hospital stay was less than 4 weeks.

Countries

China

Contacts

Primary ContactLijun Hou, MD,PhD
houlijunsmmu@163.com86 21 81885671
Backup ContactLiang Zhao, MD,PhD
15921509289@163.com86 21 81885686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026